- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04703283
Self-help Lifestyle Medicine for Insomnia
7. Januar 2021 aktualisiert von: Fiona YY Ho, Chinese University of Hong Kong
Effect of a Self-help Smartphone-based Lifestyle Intervention in Reducing Insomnia Symptoms: A Randomized Controlled Trial
This study will examine the effects of a self-help smartphone-based multi-component lifestyle medicine intervention (LM) for alleviating insomnia symptoms in a Chinese population.
Since a range of lifestyle factors are related to the pathogenesis and progression of insomnia, modifying different lifestyle factors simultaneously, such as diet, exercise, stress, and sleep which are empirically supported by previous reviews, may be effective to reduce insomnia symptoms (Reid et al., 2010; Vedaa et al., 2016).
Traditional Chinese nutritional values will be integrated into the smartphone application to increase the acceptability towards the intervention.
A prevalence study suggested that self-help interventions are preferred due to the potential stigmatization related to mental health interventions and the high cost of mental health services in Hong Kong (Lee, Tsang, & Kwok, 2007).
Nonetheless, to date, only limited self-help interventions that target lifestyle medicine for sleep-related problems are available.
Through this study, we aimed to promote evidence-based patient care and improve help-seeking behaviors and access to evidence-based lifestyle interventions for insomnia.
Studienübersicht
Status
Unbekannt
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study will be a randomized controlled trial on the effects of a self-help smartphone-based multi-component lifestyle medicine intervention for reducing insomnia symptoms in the Chinese population.
Prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support).
Assuming an alpha error of 5%, a beta error rate of 20%, and a between-group effect size of 0.77 for the Insomnia Severity Scale (Ip et al., 2020), the final sample is 28 for both groups.
With an estimation of 20% withdrawal, 70 eligible participants will be randomly assigned to either the smartphone-based multi-component lifestyle medicine intervention (LM group) or the waitlist control group (WL group) in a ratio of 1:1.
Studientyp
Interventionell
Einschreibung (Voraussichtlich)
70
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Sha Tin, Hongkong
- The Chinese University of Hong Kong
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Hong Kong residents
- Aged ≥ 18 years
- Have an Insomnia Severity Index (ISI) score ≥10, indicating at least sub threshold level of insomnia symptoms are present
- Able to read Chinese and type in Chinese or English
- Have an Internet-enabled mobile device (iOS or Android operating system)
- Are willing to provide informed consent and comply with the trial protocol
Exclusion Criteria:
- Current involvement in psychotherapy or unstable medication for sleep, depression, and/or anxiety
- Beck Depression Inventory (BDI-II) Item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk)
- Are having unsafe conditions and are not recommended for exercise or a change in diet by physicians
- Having major psychiatric, medical, or neurocognitive disorders that make participation infeasible or interfere with the adherence to the lifestyle modification
- Other untreated sleep disorders, including narcolepsy, obstructive sleep apnoea (OSA), and restless leg syndrome (RLS)/periodic leg movement disorder (PLMD) based on the cut-off scores (≥ 7 on narcolepsy; ≥ 15 on OSA; ≥ 7 on RLS/PLMD) of individual sections in SLEEP-50
- Shift work, pregnancy, work, family, or other commitments that interfere with regular night-time sleep patterns
- Hospitalization
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Kontrollgruppe Warteliste
Teilnehmer der Kontrollgruppe auf der Warteliste erhalten die Intervention nach der unmittelbaren Nachbehandlungsbeurteilung
|
|
|
Experimental: Lifestyle Medicine Group
Lifestyle intervention with components including exercise, diet, stress management, and sleep management
|
Lifestyle intervention with components including exercise, diet, stress management, and sleep management
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in the Insomnia Severity Index (ISI)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
ISI is a 7-item scale designed to evaluate perceived insomnia severity.
Ratings on the 5-point Likert scale are obtained on the perceived severity of sleep-onset, sleep-maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeably of impairment attributed to the sleep problem, and level of distress caused by the sleep problem.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Selbst entwickelte Umfrage
Zeitfenster: Grundlinie
|
Die selbst entwickelte Umfrage wird Informationen sammeln, einschließlich demografischer Informationen (z. B. Alter, Geschlecht, Bildungsniveau, Arbeitsbranche, Beziehungsstatus und Wohnort), Substanzkonsum, Body-Mass-Index (BMI), Ruheaktivitätsmuster und soziale Rhythmen usw.
|
Grundlinie
|
|
Change in the Hospital Anxiety and Depression Scale (HADS)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
The HADS, a self-reporting questionnaire used for assessing the level of depressive and anxiety symptoms over the past week on a 4-point scale.
The HADS consists of two parts: an anxiety subscale (HADS-A) and a depression subscale (HADS-D), both of which have seven items.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
|
Change in the Short Form (Six-Dimension) Health Survey (SF-6D)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
SF-6D is a preference-based single index measure of health.
A six-digit number represents each SF-6D health state, each digit denotes the level of one of six SF-6D dimensions: physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
|
Change in the Health-Promoting Lifestyle Profile (HPLP II)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
The 52-item HPLPII is composed of a total scale and six subscales to measure behaviors in the theorized dimensions of health-promoting lifestyle: spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility, and stress management.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
|
Change in the Sheehan Disability Scale (SDS)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
|
Change in the Credibility-Expectancy Questionnaire (CEQ)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
The 6-item CEQ yielded ratings of treatment credibility, acceptability/satisfaction, and expectations for success.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
|
Change in the Pittsburgh sleep quality index (PSQI)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
Participants' subjective sleep disturbance over the past month will be assessed using PSQI.
PSQI consists of 19 self-rating items that can be categorized into seven components, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction.
Each component is scored on a 4-point Likert scale (0-3).
The sum of the seven components results in a global score of 21.
A high score indicates worse sleep quality.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
|
Change in the Consensus Sleep Diary (CSD-M)
Zeitfenster: Baseline, immediately post-intervention, and 1-month post-intervention
|
The standardized sleep diary records sleep time, wake time, perceived sleeping quality, use of hypnotics, etc. on a daily basis.
Variables derived from the sleep diary include sleep onset latency (SOL), wake after sleep onset (WASO), total wake time (TWT), total sleep time (TST), sleep efficiency (SE), etc.
|
Baseline, immediately post-intervention, and 1-month post-intervention
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Voraussichtlich)
1. März 2021
Primärer Abschluss (Voraussichtlich)
1. August 2021
Studienabschluss (Voraussichtlich)
1. Oktober 2021
Studienanmeldedaten
Zuerst eingereicht
7. Januar 2021
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
7. Januar 2021
Zuerst gepostet (Tatsächlich)
11. Januar 2021
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
11. Januar 2021
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
7. Januar 2021
Zuletzt verifiziert
1. Januar 2021
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- PSY012
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .